Clark M L, Paredes A, Costiloe J P, Wood F
J Clin Pharmacol. 1977 Aug-Sep;17(8-9):529-36. doi: 10.1002/j.1552-4604.1977.tb05646.x.
In a double-blind, placebo-controlled study, an attempt was made to evaluate butaclamol in chronic schizophrenic patients using chlorpromazine (CPZ) as the standard comparative drug. With doses up to 50 mg/day, butaclamol was shown to have significant antipsychotic activity comparable to CPZ but with a much higher incidence of extrapyramidal signs. A more reasonable maintenance dose may be in the range of 5 to 20 mg/day. Rebound insomnia was noted again with butaclamol, which warrants further study.
在一项双盲、安慰剂对照研究中，尝试以氯丙嗪（CPZ）作为标准对照药物，对慢性精神分裂症患者使用布他莫尔进行评估。当剂量高达50毫克/天时，布他莫尔显示出与CPZ相当的显著抗精神病活性，但锥体外系症状的发生率要高得多。更合理的维持剂量可能在5至20毫克/天的范围内。再次注意到布他莫尔会引起反弹性失眠，这值得进一步研究。
